Staphylococcus aureus (S. aureus) is a causative agent of various diseases such as pneumonia, gastroenteritis, endocarditis, and septic shock. Among them, methicillin-resistant Staphylococcus aureus (MRSA) is a representative antibiotic-resistant Staphylococcus aureus. Infectious diseases caused by this bacterium show high morbidity and mortality worldwide and are gradually increasing.
MRSA is an English acronym for ‘Methicillin-Resistant Staphylococcus aureus’, which refers to malignant bacteria that are strongly resistant to almost all antibiotics, and is also known as a superbug.
3bix and the research team intensively analyzed the growth inhibitory factors of methicillin-resistant Staphylococcus aureus through Next Generation Sequencing (NGS) and transcriptome analysis.
Microorganisms living in the human intestine decompose dietary fiber to produce short chain fatty acids, which are an energy source for intestinal mucosal epithelial cells and play a good role in maintaining health through antibacterial action and immune regulation. do. Propionate, one of the short fatty acids, can suppress MRSA, and it was confirmed that it shows a calming effect that prevents bacteria from multiplying by targeting genes of major metabolic pathways.
Existing antibiotic treatments have limitations in treating Staphylococcus aureus infections due to low tissue absorption, slow bactericidal efficacy, and difficulty in controlling antibiotic-resistant bacteria such as MRSA.
Park Joon-hyung, CEO of 3vix, said, “Through this study, propionate weakens the growth of MRSA by changing the metabolic pathway of MRSA and can be used as a new concept bacteriostatic agent that is biocompatible and less likely to cause resistance to prevent and treat MRSA infectious diseases. confirmed,” he said.
ⓒ Acrofan All Right Reserved.